Here, we report four children with AML with RUNX1::RUNX1T1 and KIT mutations, who mostly were refractory to demethylation drugs (HMAs) and donor lymphocyte infusion (DLI), who were treated with avapritinib as a preemptive intervention after allo-HSCT. This evidence concerns the gene RUNX1 and acute myeloid leukemia.